Identification

Name
Captopril
Accession Number
DB01197  (APRD00164)
Type
Small Molecule
Groups
Approved
Description

Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.

Structure
Thumb
Synonyms
  • (2S)-1-[(2S)-2-Methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
  • Acepress
  • Apopril
  • Captolane
  • Captoprilum
  • Captopryl
  • Captoril
  • Cesplon
  • CP
  • D-2-Methyl-3-mercaptopropanoyl-L-proline
  • D-3-Mercapto-2-methylpropanoyl-L-proline
  • Dilabar
  • Garranil
  • Hypertil
  • L-Captopril
  • Lopirin
  • Tenosbon
  • Tensobon
  • Tensoprel
External IDs
C09AA01 / SA-333 / SQ 14,225 / SQ-14225
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bci Captopril TabletsTablet50 mgOralBaker Cummins IncNot applicableNot applicableCanada
Bci Captopril TabletsTablet25 mgOralBaker Cummins IncNot applicableNot applicableCanada
Bci Captopril TabletsTablet100 mgOralBaker Cummins IncNot applicableNot applicableCanada
Bci Captopril TabletsTablet12.5 mgOralBaker Cummins IncNot applicableNot applicableCanada
Capoten Tab 100mgTablet100 mgOralBristol Myers Squibb1981-12-312008-02-05Canada
Capoten Tab 12.5mgTablet12.5 mgOralBristol Myers Squibb1990-12-312009-06-29Canada
Capoten Tab 25mgTablet25 mgOralBristol Myers Squibb1981-12-312011-11-01Canada
Capoten Tab 50mgTablet50 mgOralBristol Myers Squibb1981-12-312010-12-16Canada
CaptoprilTablet50 mgOralSorres Pharma Inc2000-10-262014-06-20Canada
CaptoprilTablet100 mgOralPharmel Inc1998-09-03Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-capto Tab 100mgTablet100 mgOralApotex Corporation1990-12-31Not applicableCanada
Apo-capto Tab 12.5mgTablet12.5 mgOralApotex Corporation1990-12-31Not applicableCanada
Apo-capto Tab 25mgTablet25 mgOralApotex Corporation1990-12-31Not applicableCanada
Apo-capto Tab 50mgTablet50 mgOralApotex Corporation1990-12-31Not applicableCanada
Apo-capto Tab 6.25mgTablet6.25 mgOralApotex Corporation1992-12-31Not applicableCanada
Bupropion HydrochlorideTablet, film coated75 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
CaptoprilTablet50 mg/1OralLegacy Pharmaceutical Packaging2009-09-11Not applicableUs
CaptoprilTablet12.5 mg/1OralSandoz2016-07-01Not applicableUs
CaptoprilTablet50 mg/1OralUnit Dose Services1996-02-13Not applicableUs
CaptoprilTablet25 mg/1OralAmerincan Health Packaging2017-11-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Captopril and HydrochlorothiazideCaptopril (50 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralPhysicians Total Care, Inc.2003-10-07Not applicableUs
Captopril and HydrochlorothiazideCaptopril (50 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralMylan Pharmaceuticals1997-12-29Not applicableUs
Captopril and HydrochlorothiazideCaptopril (25 mg/1) + Hydrochlorothiazide (15 mg/1)TabletOralMylan Pharmaceuticals1997-12-29Not applicableUs
Captopril and HydrochlorothiazideCaptopril (50 mg/1) + Hydrochlorothiazide (15 mg/1)TabletOralMylan Pharmaceuticals1997-12-29Not applicableUs
Captopril and HydrochlorothiazideCaptopril (25 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralPhysicians Total Care, Inc.2007-07-12Not applicableUs
Captopril and HydrochlorothiazideCaptopril (25 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralMylan Pharmaceuticals1997-12-29Not applicableUs
International/Other Brands
Acepress (Bernofarm (Indonesia), BMS (Italy)) / Acepril (BMS (United Kingdom)) / Alopresin / Apopril / Capoten (Bristol-Myers Squibb, Par) / Captolane (Sanofi-Aventis (France)) / Captoril (Novopharm (Canada)) / Cesplon (Esteve (Spain)) / Dilabar (Qualigen (Spain)) / Garranil (Aristegui (Spain)) / Hipertil (Normal (Portugal)) / Hypertil (Normal (Portugal)) / Lopirin (BMS (Germany,Switzerland)) / Lopril (Orion (Finland), BMS (France)) / Tenosbon / Tensoprel (Rubio (Spain))
Categories
UNII
9G64RSX1XD
CAS number
62571-86-2
Weight
Average: 217.285
Monoisotopic: 217.077264041
Chemical Formula
C9H15NO3S
InChI Key
FAKRSMQSSFJEIM-RQJHMYQMSA-N
InChI
InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
IUPAC Name
(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
SMILES
C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

Pharmacology

Indication

For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.

Structured Indications
Pharmacodynamics

Captopril, an ACE inhibitor, antagonizes the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain its effects by causing increased vasodilation and decreased blood pressure.

Mechanism of action

There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Captopril, one of the few ACE inhibitors that is not a prodrug, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Captopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors. Captopril’s affinity for ACE is approximately 30,000 times greater than that of ATI.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
U72 kDa type IV collagenase
inhibitor
Human
UMatrix metalloproteinase-9
inhibitor
Human
ULeukotriene A-4 hydrolase
inhibitor
Human
UB1 bradykinin receptorNot AvailableHuman
Absorption

60-75% in fasting individuals; food decreases absorption by 25-40% (some evidence indicates that this is not clinically significant)

Volume of distribution
Not Available
Protein binding

25-30% bound to plasma proteins, primarily albumin

Metabolism

Hepatic. Major metabolites are captopril-cysteine disulfide and the disulfide dimer of captopril. Metabolites may undergo reversible interconversion.

Route of elimination
Not Available
Half life

2 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include emesis and decreased blood pressure. Side effects include dose-dependent rash (usually maculopapular), taste alterations, hypotension, gastric irritation, cough, and angioedema.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Captopril Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Captopril.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Captopril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Captopril.Approved, Investigational
AbirateroneThe serum concentration of Captopril can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the hypotensive activities of Captopril.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Captopril.Approved, Investigational
AcemetacinThe therapeutic efficacy of Captopril can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Captopril can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Captopril.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Captopril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Captopril.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Captopril.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Captopril.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Captopril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Captopril.Approved
AlmasilateAlmasilate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Captopril.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Captopril.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AloxiprinThe therapeutic efficacy of Captopril can be decreased when used in combination with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Captopril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Captopril.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmbrisentanCaptopril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Captopril.Experimental, Investigational
AmifostineCaptopril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Captopril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Captopril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Captopril.Approved
Aminosalicylic AcidThe therapeutic efficacy of Captopril can be decreased when used in combination with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Captopril can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Captopril.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Captopril.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Captopril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Captopril.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Captopril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Captopril.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Captopril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Captopril is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Captopril.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Captopril.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Captopril.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Captopril.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Captopril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Captopril.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Captopril.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Captopril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Captopril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Captopril.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Captopril.Approved, Investigational
ArtemetherThe metabolism of Captopril can be decreased when combined with Artemether.Approved
AtenololAtenolol may increase the hypotensive activities of Captopril.Approved
AtomoxetineThe metabolism of Captopril can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Captopril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Captopril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Captopril.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Captopril is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Captopril.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Captopril.Approved, Investigational
AzosemideAzosemide may increase the hypotensive activities of Captopril.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Captopril.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Captopril.Experimental
BarbitalBarbital may increase the hypotensive activities of Captopril.Illicit
BarnidipineCaptopril may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Captopril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Captopril.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Captopril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Captopril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Captopril.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Captopril.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Captopril.Approved
BepridilCaptopril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Captopril can be decreased when combined with Betaxolol.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Captopril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Captopril.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Captopril.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Captopril.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololBisoprolol may increase the hypotensive activities of Captopril.Approved
BoceprevirThe serum concentration of Captopril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Captopril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Captopril.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Captopril.Approved
BQ-123Captopril may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Captopril.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Captopril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Captopril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Captopril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Captopril.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Captopril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Captopril.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Captopril.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Captopril.Experimental
BumetanideBumetanide may increase the hypotensive activities of Captopril.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Captopril.Approved, Investigational
BupranololCaptopril may increase the hypotensive activities of Bupranolol.Approved
BupropionThe metabolism of Captopril can be decreased when combined with Bupropion.Approved
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Captopril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Captopril.Approved
CadralazineCadralazine may increase the hypotensive activities of Captopril.Experimental
CafedrineCaptopril may increase the hypotensive activities of Cafedrine.Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateCalcium silicate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Captopril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Captopril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Captopril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Captopril.Experimental
CarbamazepineThe metabolism of Captopril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Captopril can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Captopril.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Captopril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Captopril.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Captopril.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Captopril.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Captopril.Experimental
CelecoxibThe metabolism of Captopril can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCaptopril may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe metabolism of Captopril can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Captopril.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Captopril.Investigational, Withdrawn
ChlorpromazineThe metabolism of Captopril can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Captopril.Approved
CholecalciferolThe metabolism of Captopril can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Captopril.Approved
CicletanineCaptopril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCaptopril may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Captopril.Approved, Investigational
CimetidineThe metabolism of Captopril can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Captopril can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe risk or severity of ventricular arrhythmias can be increased when Captopril is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe metabolism of Captopril can be decreased when combined with Citalopram.Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Captopril.Approved
ClemastineThe metabolism of Captopril can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Captopril is combined with Clevidipine.Approved, Investigational
ClobazamThe metabolism of Captopril can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Captopril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Captopril.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Captopril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Captopril.Approved
CloranololCaptopril may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Captopril can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Captopril can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Captopril can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Captopril can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Captopril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Captopril.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Captopril.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Captopril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Captopril.Approved, Investigational
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Captopril.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Captopril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Captopril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Captopril.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Captopril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Captopril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Captopril.Investigational
DarifenacinThe metabolism of Captopril can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Captopril can be increased when it is combined with Darunavir.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Captopril.Approved, Investigational
DelaprilCaptopril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Captopril.Approved
DersalazineThe therapeutic efficacy of Captopril can be decreased when used in combination with Dersalazine.Investigational
DeserpidineCaptopril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Captopril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Captopril.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Captopril.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Captopril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Captopril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Captopril.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Captopril.Approved, Investigational
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Captopril.Approved, Investigational
DiethylnorspermineCaptopril may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Captopril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Captopril.Experimental
DiflunisalThe therapeutic efficacy of Captopril can be decreased when used in combination with Diflunisal.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Captopril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Captopril.Approved, Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Captopril.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Captopril.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Captopril.Approved, Withdrawn
DinutuximabThe risk or severity of adverse effects can be increased when Captopril is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe metabolism of Captopril can be decreased when combined with Diphenhydramine.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Captopril.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Captopril.Approved
DosulepinThe metabolism of Captopril can be decreased when combined with Dosulepin.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Captopril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Captopril.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Captopril.Approved, Investigational
DronedaroneThe metabolism of Captopril can be decreased when combined with Dronedarone.Approved
DrospirenoneCaptopril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Captopril.Withdrawn
DuloxetineCaptopril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Captopril.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Captopril.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Captopril.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Captopril.Approved
EfonidipineCaptopril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EliglustatThe metabolism of Captopril can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Captopril is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Captopril.Approved, Vet Approved
EnalaprilatCaptopril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Captopril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Captopril.Approved, Investigational
EpanololCaptopril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Captopril.Approved
EpitizideThe risk or severity of hypotension can be increased when Epitizide is combined with Captopril.Experimental
EplerenoneEplerenone may increase the hyperkalemic activities of Captopril.Approved
EpoprostenolCaptopril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Captopril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Captopril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Captopril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Captopril.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Captopril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Captopril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Captopril.Approved, Investigational
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Captopril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Captopril.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Captopril.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Captopril.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Captopril.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Captopril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Captopril.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Captopril.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Captopril.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Captopril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Captopril.Investigational, Nutraceutical
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Captopril.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Captopril.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Captopril.Experimental
FelodipineFelodipine may increase the hypotensive activities of Captopril.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Captopril.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Captopril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Captopril.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Captopril.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Captopril.Experimental
Ferulic acidCaptopril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Captopril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Captopril.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Captopril.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Captopril.Experimental
FluoxetineThe metabolism of Captopril can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Captopril.Approved, Investigational
FluvoxamineThe metabolism of Captopril can be decreased when combined with Fluvoxamine.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Captopril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Captopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Captopril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Captopril.Approved, Vet Approved
GarlicThe serum concentration of Captopril can be decreased when it is combined with Garlic.Approved, Nutraceutical
GuacetisalThe therapeutic efficacy of Captopril can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Captopril.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Captopril.Approved
GuanazodineCaptopril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Captopril.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Captopril.Approved, Investigational
GuanoclorCaptopril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzCaptopril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanCaptopril may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe metabolism of Captopril can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Captopril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Captopril.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Captopril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Captopril is combined with Heparin.Approved, Investigational
HexamethoniumCaptopril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Captopril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Captopril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Captopril.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Captopril.Experimental
HydralazineHydralazine may increase the hypotensive activities of Captopril.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Captopril.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Captopril.Approved, Investigational
HydrotalciteHydrotalcite can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Captopril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Captopril.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Captopril.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Captopril.Approved, Investigational
ImidaprilCaptopril may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Captopril.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Captopril.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Captopril.Approved
IndenololCaptopril may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Captopril can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Captopril.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Captopril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Captopril.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Captopril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Captopril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Captopril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Captopril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Captopril.Approved, Investigational
IronIron can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Captopril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Captopril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Captopril.Approved, Vet Approved
IsoniazidThe metabolism of Captopril can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Captopril.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Captopril.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Captopril.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Captopril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Captopril.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Captopril.Experimental
KetanserinKetanserin may increase the hypotensive activities of Captopril.Investigational
KetoconazoleThe metabolism of Captopril can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Captopril.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Captopril.Approved
LabetalolLabetalol may increase the hypotensive activities of Captopril.Approved
LacidipineCaptopril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Captopril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Captopril.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Captopril.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Captopril.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Captopril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Captopril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Captopril.Approved, Investigational
LevodopaCaptopril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Captopril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Captopril.Approved
LinsidomineCaptopril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Captopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Captopril.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Captopril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Captopril.Experimental
LofexidineCaptopril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Captopril.Experimental
LopinavirThe metabolism of Captopril can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Captopril can be decreased when combined with Lorcaserin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Captopril.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Captopril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Captopril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Captopril.Approved, Investigational
LumefantrineThe metabolism of Captopril can be decreased when combined with Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Captopril.Approved, Investigational
MacitentanCaptopril may increase the hypotensive activities of Macitentan.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Captopril.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineCaptopril may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Captopril.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Captopril.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Captopril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Captopril.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Captopril.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Captopril.Approved
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Captopril.Experimental, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Captopril.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Captopril can be decreased when used in combination with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Captopril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Captopril.Approved, Investigational, Withdrawn
MethadoneThe metabolism of Captopril can be decreased when combined with Methadone.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Captopril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Captopril.Approved
MethohexitalMethohexital may increase the hypotensive activities of Captopril.Approved
MethoserpidineCaptopril may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe metabolism of Captopril can be decreased when combined with Methotrimeprazine.Approved, Investigational
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Captopril.Approved
Methyl salicylateThe therapeutic efficacy of Captopril can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Captopril.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Captopril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Captopril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Captopril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Captopril.Approved
MetipranololCaptopril may increase the hypotensive activities of Metipranolol.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Captopril.Approved
MetoprololThe metabolism of Captopril can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineCaptopril may increase the hypotensive activities of Metyrosine.Approved
MibefradilCaptopril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Captopril.Approved, Illicit
MidostaurinThe metabolism of Captopril can be decreased when combined with Midostaurin.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Captopril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Captopril.Approved, Investigational
MirabegronThe metabolism of Captopril can be decreased when combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Captopril.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Captopril.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Captopril.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Captopril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Captopril.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Captopril.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Captopril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Captopril.Approved, Investigational
MuzolimineCaptopril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Captopril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Captopril.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Captopril.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Captopril.Approved
NadololCaptopril may increase the hypotensive activities of Nadolol.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Captopril.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Captopril.Approved
NaftopidilCaptopril may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Captopril.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Captopril.Approved, Vet Approved
NebivololCaptopril may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Captopril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Captopril.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Captopril is combined with Nesiritide.Approved, Investigational
NevirapineThe metabolism of Captopril can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Captopril.Withdrawn
NicardipineThe metabolism of Captopril can be decreased when combined with Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Captopril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Captopril.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Captopril.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Captopril.Approved
NiguldipineCaptopril may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Captopril can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineCaptopril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Captopril.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Captopril.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Captopril.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Captopril.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Captopril.Approved
NitroaspirinThe therapeutic efficacy of Captopril can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Captopril.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Captopril.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Captopril.Approved, Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Captopril.Approved
ObinutuzumabCaptopril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Captopril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Captopril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Captopril.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Captopril.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Captopril.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Captopril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Captopril.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Captopril.Approved
OxprenololCaptopril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Captopril.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Captopril.Approved, Vet Approved
PanobinostatThe serum concentration of Captopril can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Captopril.Approved, Investigational
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Captopril.Approved
PargylinePargyline may increase the hypotensive activities of Captopril.Approved
ParoxetineThe metabolism of Captopril can be decreased when combined with Paroxetine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Captopril.Approved, Investigational
Patent BlueThe therapeutic efficacy of Captopril can be decreased when used in combination with Patent Blue.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Captopril.Approved
Peginterferon alfa-2bThe serum concentration of Captopril can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololCaptopril may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Captopril.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Captopril.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Captopril.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Captopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Captopril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Captopril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Captopril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Captopril.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Captopril.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Captopril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Captopril.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Captopril can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Captopril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Captopril.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Captopril.Approved
PindololPindolol may increase the hypotensive activities of Captopril.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Captopril.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Captopril.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Captopril.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Captopril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Captopril.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Captopril.Experimental
PitolisantThe metabolism of Captopril can be decreased when combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Captopril.Withdrawn
Platelet Activating FactorCaptopril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Captopril.Approved
PotassiumPotassium may increase the hyperkalemic activities of Captopril.Approved, Investigational
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Captopril.Approved
Potassium ChloridePotassium Chloride may increase the hyperkalemic activities of Captopril.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Captopril.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Captopril.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Captopril.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Captopril.Approved
PregabalinThe risk or severity of angioedema can be increased when Captopril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Captopril.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Captopril.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Captopril.Experimental
PromazineThe metabolism of Captopril can be decreased when combined with Promazine.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Captopril.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Captopril.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Captopril.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Captopril.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Captopril.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Captopril.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Captopril.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Captopril.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Captopril is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Captopril.Approved, Investigational
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Captopril.Approved
QuinidineThe metabolism of Captopril can be decreased when combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Captopril can be decreased when combined with Quinine.Approved
RamiprilRamipril may increase the hypotensive activities of Captopril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Captopril.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Captopril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Captopril.Approved
RemikirenRemikiren may increase the hypotensive activities of Captopril.Approved
RescinnamineCaptopril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Captopril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Captopril.Approved, Experimental, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Captopril.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Captopril.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Captopril.Approved
RisperidoneCaptopril may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Captopril can be decreased when combined with Ritonavir.Approved, Investigational
RituximabCaptopril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Captopril.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Captopril can be decreased when combined with Rolapitant.Approved, Investigational
RopiniroleThe metabolism of Captopril can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Captopril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Captopril.Approved
RucaparibThe metabolism of Captopril can be decreased when combined with Rucaparib.Approved, Investigational
SacubitrilThe risk or severity of angioedema can be increased when Captopril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Captopril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Captopril.Approved
Salicylic acidThe therapeutic efficacy of Captopril can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Captopril.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Captopril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Captopril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Captopril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Captopril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Captopril.Approved, Investigational, Vet Approved
SelexipagCaptopril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Captopril.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Captopril.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Captopril.Investigational
SertralineThe metabolism of Captopril can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Captopril.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Captopril.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Captopril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Captopril.Approved
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Captopril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Captopril.Approved, Investigational
SitaxentanCaptopril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Captopril is combined with Sodium aurothiomalate.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateCaptopril may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Captopril.Approved
SpiraprilCaptopril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Captopril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Captopril.Investigational
St. John's WortThe metabolism of Captopril can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe metabolism of Captopril can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Captopril.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Captopril.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Captopril.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Captopril.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Captopril.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Captopril.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Captopril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Captopril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Captopril.Approved, Investigational
TalinololCaptopril may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Captopril.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Captopril.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Captopril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Captopril.Approved, Investigational
TemocaprilCaptopril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Captopril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Captopril.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Captopril.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Captopril.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Captopril.Approved
TerbinafineThe metabolism of Captopril can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Captopril.Approved
TerlipressinCaptopril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineCaptopril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Captopril.Approved, Investigational, Withdrawn
TheodrenalineCaptopril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Captopril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Captopril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Captopril.Approved, Vet Approved
ThioridazineThe metabolism of Captopril can be decreased when combined with Thioridazine.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Captopril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Captopril.Approved
TiboloneCaptopril may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Captopril can be decreased when combined with Ticlopidine.Approved
TicrynafenCaptopril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Captopril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Captopril.Investigational
TipranavirThe serum concentration of Captopril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Captopril.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Captopril.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Captopril.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Captopril.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Captopril.Approved
TolonidineCaptopril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Captopril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Captopril.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Captopril.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Captopril.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Captopril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Captopril.Approved, Investigational
TranylcypromineThe metabolism of Captopril can be decreased when combined with Tranylcypromine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Captopril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Captopril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Captopril.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the hyperkalemic activities of Captopril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Captopril.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Captopril.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Captopril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Captopril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Captopril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Captopril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Captopril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Captopril.Investigational
Trolamine salicylateThe therapeutic efficacy of Captopril can be decreased when used in combination with Trolamine salicylate.Approved
TromethamineTromethamine can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UdenafilUdenafil may increase the antihypertensive activities of Captopril.Approved, Investigational
UnoprostoneCaptopril may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Captopril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Captopril.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Captopril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Captopril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Captopril.Approved
VenlafaxineThe metabolism of Captopril can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Captopril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Captopril.Approved, Investigational
VincamineCaptopril may increase the hypotensive activities of Vincamine.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Captopril.Approved, Investigational
VinpocetineCaptopril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideCaptopril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineCaptopril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Captopril.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Captopril.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Captopril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Captopril.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Captopril can be decreased when combined with Ziprasidone.Approved
ZofenoprilCaptopril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Captopril.Withdrawn
Food Interactions
  • Captopril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
  • Food decreases absorption by 25 - 40%. Clinical significance is debatable.
  • Herbs that may attenuate the antihypertensive effect of captopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of captopril.

References

Synthesis Reference

Charles M. Zepp, "Methods for preparing captopril and its analogues." U.S. Patent US5166361, issued July, 1981.

US5166361
General References
  1. Atkinson AB, Robertson JI: Captopril in the treatment of clinical hypertension and cardiac failure. Lancet. 1979 Oct 20;2(8147):836-9. [PubMed:90928]
  2. Patchett AA, Harris E, Tristram EW, Wyvratt MJ, Wu MT, Taub D, Peterson ER, Ikeler TJ, ten Broeke J, Payne LG, Ondeyka DL, Thorsett ED, Greenlee WJ, Lohr NS, Hoffsommer RD, Joshua H, Ruyle WV, Rothrock JW, Aster SD, Maycock AL, Robinson FM, Hirschmann R, Sweet CS, Ulm EH, Gross DM, Vassil TC, Stone CA: A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280-3. [PubMed:6253826]
  3. Smith CG, Vane JR: The discovery of captopril. FASEB J. 2003 May;17(8):788-9. [PubMed:12724335]
External Links
Human Metabolome Database
HMDB0015328
KEGG Drug
D00251
PubChem Compound
44093
PubChem Substance
46506879
ChemSpider
40130
BindingDB
21642
ChEBI
3380
ChEMBL
CHEMBL1560
Therapeutic Targets Database
DAP000589
PharmGKB
PA448780
HET
X8Z
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Captopril
ATC Codes
C09AA01 — CaptoprilC09BA01 — Captopril and diuretics
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors
PDB Entries
1j37 / 2x8z / 3lus / 4c1d / 4c1f / 4c1h / 4c2p / 4dpr / 4exs / 4pqa
show 1 more
MSDS
Download (37.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentGlioblastomas1
1CompletedTreatmentHigh Blood Pressure (Hypertension)1
1Not Yet RecruitingDiagnosticCardiomyopathy With Unknown Etiology1
1TerminatedBasic ScienceHigh Blood Pressure (Hypertension) / Multiple System Atrophy (MSA) / Progressive autonomic failure1
1WithdrawnPreventionShigellosis1
1WithdrawnTreatmentCutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides and Sezary Syndrome / Stage IIB Mycosis Fungoides and Sezary Syndrome / Stage IIIA Mycosis Fungoides and Sezary Syndrome / Stage IIIB Mycosis Fungoides and Sezary Syndrome / Stage IVA Mycosis Fungoides and Sezary Syndrome / Stage IVB Mycosis Fungoides and Sezary Syndrome1
1, 2Active Not RecruitingBasic ScienceType 2 Diabetes Mellitus1
1, 2CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
2RecruitingTreatmentAcute myeloid leukaemia (in remission) / Aplastic Anaemia (AA) / Chronic Myelomonocytic Leukemia / Indolent Non-Hodgkin's Lymphomas / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Neoplasms, Malignant / Plasma Cell Myeloma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ring Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts1
2TerminatedSupportive CareLung Cancers / Pulmonary Complications / Radiation Fibrosis1
2TerminatedTreatmentPemphigus Vulgaris (PV)1
2Unknown StatusTreatmentHeart Diseases1
2, 3CompletedTreatmentDiabetic Nephropathies1
3CompletedSupportive CareCancers1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3CompletedTreatmentPsoriasis2
3RecruitingPreventionAcute Myeloid Leukemia in Children / Bone Tumors / Cardiotoxicity1
4CompletedNot AvailableType 2 Diabetes Mellitus1
4CompletedDiagnosticHyperaldosteronism1
4CompletedHealth Services ResearchKidney Diseases1
4CompletedTreatmentHeart Failure, Unspecified / Ventricular Dysfunction, Left1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Induction of intra-operative hypotension1
4CompletedTreatmentPreeclampsia1
4Unknown StatusTreatmentAortic Valve Stenosis1
Not AvailableCompletedOtherHyperparathyroidism1
Not AvailableUnknown StatusNot AvailableArterial Hypertension / Diabetes Mellitus (DM)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Apotheca Inc.
  • Apothecon
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Caremark LLC
  • Changzhou Pharmaceutical Factory
  • Comprehensive Consultant Services Inc.
  • Dept Health Central Pharmacy
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • E.R. Squibb and Sons LLC
  • Egis Pharmaceuticals Public Ltd. Co.
  • Eon Labs
  • Heartland Repack Services LLC
  • Innovative Manufacturing and Distribution Services Inc.
  • Lake Erie Medical and Surgical Supply
  • Legacy Pharmaceuticals Packaging LLC
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacy Service Center
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Qualitest
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • Stason Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Tya Pharmaceuticals
  • UDL Laboratories
  • Vangard Labs Inc.
  • West-Ward Pharmaceuticals
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral12.5 mg
TabletOral25 mg
TabletOral50 mg
TabletOral6.25 mg
Tablet, film coatedOral75 mg/1
TabletOral100 mg/1
TabletOral12.5 mg/1
TabletOral15 mg/1
TabletOral25 mg/1
TabletOral30 mg/1
TabletOral50 mg/1
TabletOral
Prices
Unit descriptionCostUnit
Captopril powder22.03USD g
Capoten 100 mg tablet4.53USD tablet
Capoten 12.5 mg tablet1.8USD tablet
Captopril 100 mg tablet1.53USD tablet
Captopril 50 mg tablet1.14USD tablet
Capoten 25 mg tablet1.13USD tablet
Capoten 50 mg tablet1.13USD tablet
Apo-Capto 100 mg Tablet1.09USD tablet
Mylan-Captopril 100 mg Tablet1.09USD tablet
Novo-Captoril 100 mg Tablet1.09USD tablet
Nu-Capto 100 mg Tablet1.09USD tablet
Captopril 25 mg tablet0.67USD tablet
Captopril 12.5 mg tablet0.62USD tablet
Apo-Capto 50 mg Tablet0.59USD tablet
Mylan-Captopril 50 mg Tablet0.59USD tablet
Novo-Captoril 50 mg Tablet0.59USD tablet
Nu-Capto 50 mg Tablet0.59USD tablet
Apo-Capto 25 mg Tablet0.31USD tablet
Mylan-Captopril 25 mg Tablet0.31USD tablet
Novo-Captoril 25 mg Tablet0.31USD tablet
Nu-Capto 25 mg Tablet0.31USD tablet
Apo-Capto 12.5 mg Tablet0.22USD tablet
Mylan-Captopril 12.5 mg Tablet0.22USD tablet
Novo-Captoril 12.5 mg Tablet0.22USD tablet
Nu-Capto 12.5 mg Tablet0.22USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5238924No1993-08-242010-08-24Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)103-104Ondetti, M.A. and Cushman, D.W.; U.S. Patent 4,046,889; September 6, 1977; assigned t o E.R. Squibb & Sons, Inc. Ondetti, M.A. and Cushman, D.W.; U.S. Patent 4,105,776; August 8,1978; assigned to E.R. Squibb & Sons, Inc. Ondetti, M.A. and Cushman, D.W.; U.S. Patent 4,154,840; May 15,1979; assigned to E.R. Squibb & Sons, Inc.
water solubilityFreely solubleNot Available
logP0.34RANADIVE,SA ET AL. (1992)
Predicted Properties
PropertyValueSource
Water Solubility4.52 mg/mLALOGPS
logP1.02ALOGPS
logP0.73ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)4.02ChemAxon
pKa (Strongest Basic)-1.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity54.63 m3·mol-1ChemAxon
Polarizability21.72 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.97
Blood Brain Barrier+0.6467
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.6276
P-glycoprotein inhibitor INon-inhibitor0.8448
P-glycoprotein inhibitor IINon-inhibitor0.7415
Renal organic cation transporterNon-inhibitor0.8073
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6293
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9102
CYP450 2D6 inhibitorNon-inhibitor0.9537
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9049
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8975
Ames testNon AMES toxic0.8164
CarcinogenicityNon-carcinogens0.9434
BiodegradationNot ready biodegradable0.6577
Rat acute toxicity1.7403 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9604
hERG inhibition (predictor II)Non-inhibitor0.9118
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0910000000-8797427ebbfead8313f9
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0940000000-26ddf220b67fb8dcdff0
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01b9-8910000000-d831e8d48402a4c5fe73
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01b9-9720000000-8218e12ef8f7e988c312

Taxonomy

Description
This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Proline and derivatives
Alternative Parents
N-acyl-L-alpha-amino acids / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Tertiary carboxylic acid amides / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Alkylthiols / Organopnictogen compounds / Organonitrogen compounds
show 3 more
Substituents
N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Proline or derivatives / N-acylpyrrolidine / Pyrrolidine carboxylic acid / Pyrrolidine carboxylic acid or derivatives / Pyrrolidine / Tertiary carboxylic acid amide / Carboxamide group
show 15 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
L-proline derivative, alkanethiol, pyrrolidinemonocarboxylic acid, N-acylpyrrolidine (CHEBI:3380)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Andujar-Sanchez M, Jara-Perez V, Camara-Artigas A: Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett. 2007 Jul 24;581(18):3449-54. Epub 2007 Jun 27. [PubMed:17618628]
  2. Dalkas GA, Marchand D, Galleyrand JC, Martinez J, Spyroulias GA, Cordopatis P, Cavelier F: Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme. J Pept Sci. 2010 Feb;16(2):91-7. doi: 10.1002/psc.1201. [PubMed:20014331]
  3. Natesh R, Schwager SL, Evans HR, Sturrock ED, Acharya KR: Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry. 2004 Jul 13;43(27):8718-24. [PubMed:15236580]
  4. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016]
  5. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321]
  6. Tzakos AG, Naqvi N, Comporozos K, Pierattelli R, Theodorou V, Husain A, Gerothanassis IP: The molecular basis for the selection of captopril cis and trans conformations by angiotensin I converting enzyme. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5084-7. Epub 2006 Aug 2. [PubMed:16889963]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rup...
Gene Name
MMP2
Uniprot ID
P08253
Uniprot Name
72 kDa type IV collagenase
Molecular Weight
73881.695 Da
References
  1. Brower GL, Levick SP, Janicki JS: Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H3057-64. Epub 2007 Feb 16. [PubMed:17308006]
  2. Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H, Hara Y: Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci. 2008 Dec;108(4):487-94. Epub 2008 Dec 5. [PubMed:19057128]
  3. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D: Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer. 1999 May 31;81(5):761-6. [PubMed:10328230]
  4. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR: Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart. 2002 Nov;88(5):525-30. [PubMed:12381651]
  5. Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA: Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol. 2005 Nov;31(9):1042-50. Epub 2005 Jul 1. [PubMed:15993560]
  6. Yamamoto D, Takai S, Hirahara I, Kusano E: Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy. Clin Chim Acta. 2010 May 2;411(9-10):762-4. doi: 10.1016/j.cca.2010.02.059. Epub 2010 Feb 22. [PubMed:20184869]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves...
Gene Name
MMP9
Uniprot ID
P14780
Uniprot Name
Matrix metalloproteinase-9
Molecular Weight
78457.51 Da
References
  1. Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H, Hara Y: Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci. 2008 Dec;108(4):487-94. Epub 2008 Dec 5. [PubMed:19057128]
  2. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR: Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart. 2002 Nov;88(5):525-30. [PubMed:12381651]
  3. Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA: Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol. 2005 Nov;31(9):1042-50. Epub 2005 Jul 1. [PubMed:15993560]
  4. Yamamoto D, Takai S, Miyazaki M: Inhibitory profiles of captopril on matrix metalloproteinase-9 activity. Eur J Pharmacol. 2008 Jul 7;588(2-3):277-9. doi: 10.1016/j.ejphar.2008.04.031. Epub 2008 May 22. [PubMed:18501888]
Details
4. Leukotriene A-4 hydrolase
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Epoxide hydrolase that catalyzes the final step in the biosynthesis of the proinflammatory mediator leukotriene B4. Has also aminopeptidase activity.
Gene Name
LTA4H
Uniprot ID
P09960
Uniprot Name
Leukotriene A-4 hydrolase
Molecular Weight
69284.64 Da
References
  1. Thunnissen MM, Andersson B, Samuelsson B, Wong CH, Haeggstrom J: Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors. FASEB J. 2002 Oct;16(12):1648-50. Epub 2002 Aug 7. [PubMed:12207002]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Peptide binding
Specific Function
This is a receptor for bradykinin. Could be a factor in chronic pain and inflammation.
Gene Name
BDKRB1
Uniprot ID
P46663
Uniprot Name
B1 bradykinin receptor
Molecular Weight
40494.29 Da
References
  1. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdos EG: Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J Biol Chem. 2002 May 10;277(19):16847-52. Epub 2002 Mar 5. [PubMed:11880373]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Other/unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Keire DA, Mariappan SV, Peng J, Rabenstein DL: Nuclear magnetic resonance studies of the binding of captopril and penicillamine by serum albumin. Biochem Pharmacol. 1993 Sep 14;46(6):1059-69. [PubMed:8216349]
  2. Lin SY, Wei YS, Li MJ, Wang SL: Effect of ethanol or/and captopril on the secondary structure of human serum albumin before and after protein binding. Eur J Pharm Biopharm. 2004 May;57(3):457-64. [PubMed:15093593]
  3. Mariee AD, Al-Shabanah O: Protective ability and binding affinity of captopril towards serum albumin in an in vitro glycation model of diabetes mellitus. J Pharm Biomed Anal. 2006 May 3;41(2):571-5. Epub 2006 Feb 15. [PubMed:16469467]
  4. Narazaki R, Harada K, Sugii A, Otagiri M: Kinetic analysis of the covalent binding of captopril to human serum albumin. J Pharm Sci. 1997 Feb;86(2):215-9. [PubMed:9040098]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Watanabe K, Sawano T, Terada K, Endo T, Sakata M, Sato J: Studies on intestinal absorption of sulpiride (1): carrier-mediated uptake of sulpiride in the human intestinal cell line Caco-2. Biol Pharm Bull. 2002 Jul;25(7):885-90. [PubMed:12132663]
  2. Temple CS, Boyd CA: Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: a functional analysis using ACE inhibitors to determine the isoform of the transporter. Biochim Biophys Acta. 1998 Aug 14;1373(1):277-81. [PubMed:9733984]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528]

Drug created on June 13, 2005 07:24 / Updated on May 26, 2018 08:54